HR
MRNA icon

Howe & Rusling’s Moderna MRNA Stock Holding History

Howe & Rusling’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-155
Closed -$18K – 761
2022
Q3 		$18K Buy
155
+1
+0.6% +$152 ﹤0.01% 441
2022
Q2 		$22K Buy
154
+4
+3% +$572 ﹤0.01% 409
2022
Q1 		$26K Hold
150
– – ﹤0.01% 386
2021
Q4 		$38K Hold
150
– – ﹤0.01% 350
2021
Q3 		$58K Hold
150
– – 0.01% 295
2021
Q2 		$35K Hold
150
– – ﹤0.01% 334
2021
Q1 		$20K Hold
150
– – ﹤0.01% 403
2020
Q4 		$16K Buy
150
+50
+50% +$5.06K ﹤0.01% 428
2020
Q3 		$7K Buy
100
+5
+5% +$349 ﹤0.01% 500
2020
Q2 		$6K Hold
95
– – ﹤0.01% 510
2020
Q1 		$3K Sell
95
-210
-69% -$4.83K ﹤0.01% 578
2019
Q4 		$6K Buy
305
+110
+56% +$1.95K ﹤0.01% 531
2019
Q3 		$3K Buy
+195
New +$2.88K ﹤0.01% 631

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Howe & Rusling's MRNA Position: Q4 2022 in Review

Howe & Rusling sold out of Moderna (MRNA) in Q4 2022, closing a stake of 155 shares — an estimated $18K sold.

Howe & Rusling first reported a position in MRNA in Q3 2019 and held it in 13 quarters. The position peaked at $58K in Q3 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Howe & Rusling reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 155 Moderna shares in Q4 2022, an estimated $18K.
  • Howe & Rusling first reported a position in Moderna in Q3 2019 and held it in 13 quarters.
  • Howe & Rusling's Moderna position peaked at $58K in Q3 2021.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.